PureTech Health : Announces Annual Results for Year Ended 31 December 2016

6 April 2017

PureTech Health plc

PureTech Health Announces Annual Results for Year Ended 31 December 2016 PureTech Health plc ("PureTech Health", LSE: PRTC), an advanced clinical stage biopharmaceutical

company, today announces its annual results for the year ended 31 December 2016. The following

information represents select highlights from the full Report, which is available on the Investor Relations section of the PureTech Health website at http://puretechhealth.com/investors-reports- presentations.php.

Period Highlights

Financial and Business Highlights

• As of 31 December 2016, PureTech Health reports a consolidated cash balance of approximately $281.5 million, with approximately $192.1 million held at the Parent Company

• Aggregate Value of Growth-Stage Holdings at 31 December 2016 increased to $380.1 million from $291.7 million at 31 December 2015, an increase of 30.3 percent. A majority of the Growth Stage Holdings Value is based on transactions including third-party investors

• PureTech Health's Asset Value (Corporate Cash + Growth-Stage Holdings Value) at 31 December 2016 is $572 million. This Asset Value does not include 15 project and concept stage programmes that are not yet formally valued by the Group

• In 2016, the Group's programmes attracted in excess of $98 million in funding, including

  $29.3 million from leading strategic and financial institutions such as Amgen Ventures, Merck Ventures BV*, Rock Springs Capital, Seventure, JAZZ Venture Partners, and Canepa Advanced Healthcare Fund

  • Vedanta Biosciences raised $50.0 million in new equity investments

  • Akili raised $42.4 million in new equity investments

• PureTech Health has average equity holdings of approximately 72 percent in its programmes, and effective control over all

• PureTech Health advanced four programmes - Alivio, Commense, Sonde, and The Sync Project - from project stage to growth stage due to achieving a level of de-risking, securing intellectual property, establishing management teams, developing a sustainable business plan and engaging key scientific founders

• PureTech Health progressed three new programmes from concept stage to project stage:

  • resTORbio - A Phase 2 clinical programme developing a treatment to address immunosenescence, an age-dependent decline in immune function (advanced to growth stage in the post-period and not included in the Growth-Stage Holdings Value as of 31 December 2016)

  • Nybo - A preclinical programme developing monoclonal antibodies to target immuno-suppressive cells in pancreatic cancer, colorectal cancer, and other solid tumours

  • Glyph - A preclinical programme developing novel approaches to enhance delivery and distribution of therapeutics via the lymphatic system

    Pipeline/Clinical Highlights

    PureTech Health is advancing a robust pipeline of late and mid-stage clinical programmes and preclinical product candidates, with several pivotal trials and human proof-of-concept studies expected to read out over the next 12 to 18 months. PureTech Health has made significant progress in advancing its eight clinical programmes and seven preclinical programmes, including:

• Akili initiated a pivotal study of Project:EVOTM in paediatric attention deficit hyperactivity disorder (ADHD), published data from two studies showing the potential benefit of its core cognitive treatment technology in targeting cognition and mood in individuals diagnosed with depression, and presented positive top line data from its Alzheimer's screen digital biomarker study in collaboration with Pfizer

• Gelesis initiated the U.S. portion of a pivotal study of Gelesis100 in people who are overweight or have obesity and presented positive top line safety data and positive satiety data from its second candidate (Gelesis200) in obesity

• Karuna announced positive results from a tolerability proof-of-concept clinical study of its lead programme for the treatment of schizophrenia and Alzheimer's disease psychosis and cognition impairment

• Vedanta commenced GMP manufacturing of its C. difficile candidate, VE303, to begin human clinical studies in 2017

• Entrega's targeted delivery platform generated positive proof-of-concept data for delivery of peptides in large animals

• Sonde completed initial development of its scalable, vocal biomarker technology and gathered data from 1,800 participants

  Team Highlights

  As PureTech Health's pipeline deepens and progresses, the Group has attracted several industry leaders to full-time positions to help take PureTech Health to the next level of growth and value realisation, including:

• Joseph Bolen, PhD, an industry leader who has advanced more than 30 medicines into clinical development and previously served as President and Chief Scientific Officer for Moderna Therapeutics and Chief Scientific Officer at Millennium, as Chief Scientific Officer of PureTech Health

• LeRoux Jooste, who has launched and commercialised several blockbuster neurology drugs, as Chief Commercial Officer of Akili

• David Pass, PharmD, who brings commercial expertise building a billion-dollar franchise across diabetes and metabolic disorders from his time with Boerhinger Ingelheim, as Chief Operating Officer of Gelesis

• Bruce L. Roberts, PhD, who brings drug discovery and development expertise and most recently served as head of Neuro-Immunology and Immune-Mediated Disease Research at Sanofi Genzyme, as Chief Scientific Officer for Vedanta Biosciences

  Intellectual Property

  PureTech Health has also significantly expanded and strengthened its IP portfolio across several programmes:

• Increased total number of patents and patent applications by 79

• Licensed key IP to strengthen coverage for its Commense, Sonde Health, and Vedanta Biosciences programmes

• Received grants of patents for Vedanta Biosciences (4), Gelesis (4), and Follica (2)

  Post Year-end Highlights

• PureTech Health entered a licensing and equity agreement with Novartis to advance two clinical-stage programmes focused on diseases related to immunosenescence, an age-related decline in immune function, in its resTORbio operating subsidiary

• Vedanta Biosciences entered into clinical translational medicine collaborations with Stanford University School of Medicine and Leiden University Medical Center

• Bharatt Chowrira, PhD, JD, who brings a strong track record of value realisation with several billion-dollar deals, joined PureTech Health in March 2017 as President and Chief of Business and Strategy

• Atul Pande, MD, who brings deep clinical expertise and most recently served as Senior Vice President, Head of Neuroscience, and Senior Advisor, Pharmaceutical R&D at GlaxoSmithKline, joined PureTech Health in February 2017 as Chief Medical Officer

  Commenting on the annual results, Daphne Zohar, Co-founder and Chief Executive Officer of PureTech Health said:

  "2016 was a year of great progress at PureTech Health. Consistent with our previously disclosed timelines, we successfully executed several important milestones, including the initiation of two pivotal studies (Akili and Gelesis) which we expect to read out later this year. We also had a number of positive clinical data readouts, including results from our Karuna tolerability proof-of-concept study, a second Gelesis clinical programme, and the presentation of top line data for Akili's Alzheimer's screen digital biomarker study in collaboration with Pfizer."

  "With the active engagement of our seasoned management team, Board of industry pioneers, and extensive network of collaborators and leading experts, we continued to strengthen and grow our robust pipeline of novel programmes to treat serious diseases caused by dysfunctions in the immune, gastrointestinal and nervous systems."

  "We enter 2017 with a strong balance sheet ($281.5 million in consolidated cash) and a focus on converting some of our exciting progress into value realisation."

  PureTech Health today released its Annual Report for the year ended 31 December 2016. In compliance with the Financial Conduct Authority's Listing Rule 9.6.3, the following documents have today been submitted to the National Storage Mechanism and will shortly be available for inspection at http://www.morningstar.co.uk/uk/NSM

• Annual Report and Accounts for the year ended 31 December 2016; and

• Notice of 2016 Annual General Meeting.

Printed copies of these documents together with the Form of Proxy have been posted to shareholders. Copies are also available electronically on the Investor Relations section of the Company's website at http://puretechhealth.com/investors-reports-presentations.php.

PureTech Health's 2017 Annual General Meeting will be held at 17.00 BST on Monday 8 May 2017 at

the St Martins Lane Hotel, 45 St Martin's Lane, London WC2N 4HX, United Kingdom.

PureTech Health will also hold its annual Capital Markets Meeting in London on Tuesday 9 May 2017 from 13.00-17.00 BST. The meeting will feature PureTech Health presenters including members of the Company's Board of Directors, senior team, key scientific advisors, and management from the Company's programmes. Please confirm if you would like to attend the Capital Markets Meeting to PureTech.Event@fticonsulting.com.

About PureTech Health

PureTech Health (PureTech Health plc, PRTC.L) is a cross-disciplinary, advanced, clinical-stage biopharmaceutical Company developing novel medicines that modulate the adaptive human systems. PureTech's therapies target the dysfunctions in the immune, nervous, and gastro-intestinal systems by addressing the underlying pathophysiology of disease from a systems perspective rather than

through a single receptor or pathway. The Company is advancing a rich pipeline that includes multiple human proof-of-concept studies and pivotal or registration studies expected to read out over the next 12-18 months. PureTech Health's growing research and development pipeline has been developed in collaboration with some of the world's leading scientific experts, who along with PureTech's experienced team and a stellar Board identify, analyse and advance very selectively the opportunities the Company believes hold the most promise for patients. This experienced and engaged team places PureTech Health at the forefront of ground-breaking science and technological innovation and leads the Company between and beyond existing disciplines. For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

# # #

For further information:

*Merck Ventures BV, Amsterdam, The Netherlands, a subsidiary of Merck KGaA, Darmstadt, Germany, known as M Ventures in the United States and Canada, is the strategic, corporate venture capital arm of Merck KGaA, Darmstadt, Germany.

Notes

(i) Nature of announcement

The financial information set out in this Annual Results Release does not constitute the Company's statutory accounts for 2016 or 2015. Any references to page numbers in this announcement are to pages within the Annual Report and Accounts. Statutory accounts for the year ended 31 December 2016 have been reported on by the Independent Auditor and will be delivered to the Registrar when due.

(ii) Forward looking statements

This Annual Results Release and the Annual Report and Accounts contain statements that are or may be forward-looking statements, including statements that relate to the Company's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk management section. These forward- looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this Annual Results Release. Except as required by law, regulatory requirement, the Listing Rules and the Disclosure Guidance and Transparency Rules, neither the Company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.